Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for cyclic depsipeptide
Most Correlated Studies
- Pancreatic duct cancer PANC-1 cells treated under hypoxia with rakicidin A and BE-43547
- Peripheral blood mononuclear cells of cutaneous T-cell lymphoma patients treated with romidepsin
- Aortic smooth muscle cells in culture treated with jasplakinolide
- HCT116 colorectal carcinoma cells treated with HDAC inhibitors largazole, SAHA, and FK228
- Uveal melanoma 92.1 cells treated with FR900359
Most Relevant Literature
- From dolastatin 13 to cyanopeptolins, micropeptins, and lyngbyastatins: the chemical biology of Ahp-…
- Trikoveramides A-C, cyclic depsipeptides from the marine cyanobacterium Symploca hydnoides.
- Trichodestruxins A-D: Cytotoxic Cyclodepsipeptides from the Endophytic Fungus Trichoderma harzianum.
- Chemical Classification of Cyclic Depsipeptides.
- Sesquiterpenes and Cyclodepsipeptides from Marine-Derived Fungus Trichoderma longibrachiatum and The…
Most Relevant Clinical Trials
- Emodepside Phase II Trial for Treatment of Onchocerciasis
- Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Li…
- Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refract…
- Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
- Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
